Could a probiotic boost breast cancer treatment? new trial aims to find out
NCT ID NCT07552181
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will take MO-03 capsules twice daily until surgery, and the main goal is to see if the cancer completely disappears by the time of surgery. The study is not yet recruiting and will follow participants for five years after surgery to track cancer recurrence and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MO-03 (a live biotherapeutic product, a type of probiotic) taken as a capsule twice daily, plus standard pembrolizumab and chemotherapy
What this could lead to
If successful, this combination could improve the chance of eliminating all cancer before surgery, potentially reducing recurrence risk in early triple-negative breast cancer.
What could go wrong
This is a small, single-site Phase II trial with no control group, so results may not be definitive. The added benefit of MO-03 over standard therapy alone is uncertain, and side effects from the combination are not yet well understood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CS Cancer at Valley Oncology Medical Group
Tarzana, California, 91356, United States
Contact
Contact
Contact
-
Cedars-Sinai Medical Center Beverly Hills
Beverly Hills, California, 90211, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
-
Hunt Cancer Institute, an Affiliate of CS Cancer
Torrance, California, 90505, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact